Following the successful completion of preclinical development for their HemoSystem blood purification platform, hemotune closed a CHF 14 million Series B2 round. The funds will be used to move into clinical trials.

在成功完成其HemoSystem血液净化平台的临床前开发后，hemotune完成了1400万瑞士法郎的B2系列。这些资金将用于临床试验。

The HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads, stands out for its ability to effectively remove large biomolecules directly from patients' bloodstreams, offering a unique approach to implement precision medicine multi-target treatments which would not be possible through drugs.

HemoSystem是一种基于纳米工程磁珠的突破性血液净化平台，它能够直接从患者的血流中有效去除大的生物分子，为实施精准医学多靶点治疗提供了一种独特的方法，这是药物无法实现的。

Hemotune initially focussed on Sepsis. Given the serious impact of sepsis, which leads to around 11 million deaths annually and is a major economic burden, the potential benefits of this innovative technology are significant for patients and healthcare systems alike. In addition to treating sepsis-related immune suppression, hemotune also plans to explore other potential uses for the platform in the future..

Hemotune最初专注于败血症。脓毒症每年导致约1100万人死亡，是一项重大的经济负担，鉴于脓毒症的严重影响，这项创新技术的潜在益处对患者和医疗保健系统都具有重要意义。除了治疗败血症相关的免疫抑制外，hemotune还计划在未来探索该平台的其他潜在用途。

The investment was led by Belmondo with continued support of existing investors including VP Venture Partners, HEMEX, OCCIDENT, Zürcher Kantonalbank, and joined by EFI. Lukas Langenegger, CEO and co-founder of hemotune AG, states: 'As we navigate through a challenging fundraising climate, the success of our Series B2 funding round underscores not only the potential of our innovative blood purification platform but also the confidence our backers have in our team and vision to revolutionize medical treatment.'.

该投资由Belmondo牵头，现有投资者（包括VP Venture Partners、HEMEX、OCCIDENT、Zürcher Kantonalbank）继续支持，EFI也加入了该投资。hemotune AG首席执行官兼联合创始人卢卡斯·兰格内格（LukasLangenegger）表示：“当我们在一个充满挑战的筹资环境中前行时，我们B2系列融资回合的成功不仅突显了我们创新血液净化平台的潜力，也突显了我们的支持者对我们的团队的信心和彻底改变医疗的愿景。”

Dr. Darius Madjdpour, founder at Belmondo comments: 'The team of hemotune has managed to develop one of the most promising platform technologies I have seen in medicine. The possibilities to tackle various diseases and enabling therapies through HemoSystem has convinced us to take the lead in this funding round.'.

Belmondo创始人Darius Madjdpour博士评论道：“hemotune团队成功开发了我在医学领域见过的最有前途的平台技术之一。通过HemoSystem解决各种疾病和实现治疗的可能性使我们确信在这一轮资助中处于领先地位。”

Cédric Barra, Senior Investment Manager at OCCIDENT adds: “This Series B2 funding will now pave the way for clinical trials. The company has done an excellent job over the last few years to get to this point and we hope that hemotune can make the therapy available to patients soon.”

OCCIDENT高级投资经理Cédric Barra补充道：“这一系列B2资金现在将为临床试验铺平道路。该公司在过去几年中为达到这一点做了出色的工作，我们希望hemotune能够很快为患者提供治疗。”

Pascal Winnen, CEO of HEMEX, asserts: 'With our established expertise as a CRO in managing global infectious disease clinical trials, we are deeply committed to hemotune's pioneering strategy for combating septic shock. We recognize the potential for broader applications of their technology to selectively filter harmful agents from the bloodstream.'.

HEMEX首席执行官帕斯卡·温恩（PascalWinnen）表示：“凭借我们作为首席风险官在管理全球传染病临床试验方面的成熟专业知识，我们坚定地致力于hemotune对抗感染性休克的开创性战略。我们认识到他们的技术有可能得到更广泛的应用，以选择性地从血液中过滤有害物质。”